Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes
…, C Soldevilla-Pico, RJ Firpi-Morell, J Lai… - Diabetes …, 2020 - Am Diabetes Assoc
OBJECTIVE The 2019 Standards of Medical Care in Diabetes suggested that patients with
nonalcoholic fatty liver disease (NAFLD) should be evaluated for liver fibrosis. However, the …
nonalcoholic fatty liver disease (NAFLD) should be evaluated for liver fibrosis. However, the …
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus
…, VC Clark, RJ Firpi-Morell, J Lai… - Journal of …, 2019 - journals.sagepub.com
Fibromax is a diagnostic tool composed of the combination of 4 non-invasive biomarker
panels for the diagnosis of steatosis (SteatoTest), necrosis and inflammation (ActiTest and …
panels for the diagnosis of steatosis (SteatoTest), necrosis and inflammation (ActiTest and …
[HTML][HTML] An unusual case of gastritis in one patient receiving PD-1 blocking therapy: coexisting immune-related gastritis and cytomegaloviral infection
J Lu, RJ Firpi-Morell, LH Dang, J Lai… - Gastroenterology …, 2018 - ncbi.nlm.nih.gov
The programmed death 1 (PD-1), programmed death ligand 1 (PD-L1) and cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4) immune checkpoints are negative regulators of T-cell …
lymphocyte-associated antigen 4 (CTLA-4) immune checkpoints are negative regulators of T-cell …
Opioid use is more common in nonalcoholic fatty liver disease patients with cirrhosis, higher BMI, and psychiatric disease
Background: Opioid use is a topic of growing concern among patients with nonalcoholic fatty
liver disease (NAFLD). Given safety concerns of opioids, proactively identifying subgroups …
liver disease (NAFLD). Given safety concerns of opioids, proactively identifying subgroups …
Acute Acalculous Cholecystitis: A Rare Presentation of Autoimmune Hepatitis and Primary Sclerosing Cholangitis Overlap Syndrome
…, J Lai, SJ Hughes, RJ Firpi-Morell… - Journal of Medical …, 2018 - journalmc.org
Lymphoplasmacytic cholecystitis (LPC) is a unique form of chronic cholecystitis, and it has
been reported in patients with medical conditions such as primary sclerosing cholangitis, …
been reported in patients with medical conditions such as primary sclerosing cholangitis, …
Predictors of Early and Late Heart Failure Post-orthotopic Liver Transplantation
…, V Kullar, A Dolganiuc, JR Vilaro, RJ Firpi-Morell… - Journal of Cardiac …, 2015 - Elsevier
Aims We aimed to retrospectively explore the risk factors of both early and late HF in OLT
and the utility of Dobutamine stress echocardiogram (DSE) in this regard. Methods Medical …
and the utility of Dobutamine stress echocardiogram (DSE) in this regard. Methods Medical …
[HTML][HTML] Elbasvir/grazoprevir in people with hepatitis C genotype 1 infection and child-pugh class B cirrhosis: the C-SALT study
IM Jacobson, F Poordad, R Firpi-Morell… - Clinical and …, 2019 - journals.lww.com
METHODS: In this 12-week, phase 2, nonrandomized, open-label study (NCT02115321;
Protocol MK-5172-059), participants with CP-B cirrhosis received EBR 50 mg plus GZR 50 mg …
Protocol MK-5172-059), participants with CP-B cirrhosis received EBR 50 mg plus GZR 50 mg …
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
…, J Ferreira, S Fink, K Finnegan, R Firpi-Morell… - The Lancet, 2019 - thelancet.com
Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease
that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown …
that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown …
Prevalence and factors associated with statin use among patients with nonalcoholic fatty liver disease in the TARGET-NASH study
…, LM Weiss, H Trinh, R Firpi-Morell… - Clinical …, 2022 - cghjournal.org
Methods Adults with NAFLD enrolled in the TARGET-NASH study, across 60 sites in the United
States, with an indication for statin therapy were included. Statin indication was based on …
States, with an indication for statin therapy were included. Statin indication was based on …
Validation of a clinical risk-based classification system in a large nonalcoholic fatty liver disease real-world cohort
…, AR Mospan, KR Reddy, R Firpi-Morell… - Clinical …, 2023 - Elsevier
Background & Aims There is an unmet need to validate simple and easily available methods
that can be used in routine practice to identify those at risk of adverse outcomes from …
that can be used in routine practice to identify those at risk of adverse outcomes from …